ZYUS Life Sciences Insider Confidence Rewarded, Stock Hits CA$72m Market Cap

ZYUS Life Sciences Corporation (CVE:ZYUS) insiders who purchased shares in the last 12 months were richly rewarded last week. The stock climbed by 11% resulting in a CA$7.8m addition to the company’s market value. Put another way, the original CA$202.1k acquisition is now worth CA$235.8k.

While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.

See our latest analysis for ZYUS Life Sciences

ZYUS Life Sciences Insider Transactions Over The Last Year

The President Brent Zettl made the biggest insider purchase in the last 12 months. That single transaction was for CA$169k worth of shares at a price of CA$0.92 each. We do like to see buying, but this purchase was made at well below the current price of CA$1.09. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.

Over the last year, we can see that insiders have bought 216.35k shares worth CA$202k. On the other hand they divested 184.00k shares, for CA$169k. In total, ZYUS Life Sciences insiders bought more than they sold over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Have ZYUS Life Sciences Insiders Traded Recently?

We saw Insiders buy shares worth CA$171k in the last three months. But that was only a smidgen more than the CA$169k worth of sales. Overall, we don't think these recent trades are particularly informative, one way or the other.

Does ZYUS Life Sciences Boast High Insider Ownership?

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. ZYUS Life Sciences insiders own 54% of the company, currently worth about CA$39m based on the recent share price. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.

So What Do The ZYUS Life Sciences Insider Transactions Indicate?

Insider purchases may have been minimal, in the last three months, but there was no selling at all. That said, the purchases were not large. But insiders have shown more of an appetite for the stock, over the last year. Judging from their transactions, and high insider ownership, ZYUS Life Sciences insiders feel good about the company's future. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. For instance, we've identified 3 warning signs for ZYUS Life Sciences (1 makes us a bit uncomfortable) you should be aware of.

But note: ZYUS Life Sciences may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.